An Entirely Subcutaneous Implantable Cardioverter–Defibrillator
Top Cited Papers
- 1 July 2010
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 363 (1), 36-44
- https://doi.org/10.1056/nejmoa0909545
Abstract
Implantable cardioverter–defibrillators (ICDs) prevent sudden death from cardiac causes in selected patients but require the use of transvenous lead systems. To eliminate the need for venous access, we designed and tested an entirely subcutaneous ICD system.This publication has 45 references indexed in Scilit:
- Performance of the St. Jude Medical Riata LeadsHeart Rhythm, 2009
- Implantable Cardioverter–Defibrillators after Myocardial InfarctionNew England Journal of Medicine, 2008
- Benefits of the Implantable Cardioverter-DefibrillatorJournal of the American College of Cardiology, 2008
- Transvenous Pacing Leads and Systemic Thromboemboli in Patients With Intracardiac ShuntsCirculation, 2006
- Complications of Implantable Cardioverter Defibrillator Therapy in 440 Consecutive PatientsPacing and Clinical Electrophysiology, 2005
- Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart FailureNew England Journal of Medicine, 2005
- Incidence and Risk Factors of Early Venous Thrombosis Associated with Permanent Pacemaker LeadsJournal of Cardiovascular Electrophysiology, 2004
- Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection FractionNew England Journal of Medicine, 2002
- Complications of third-generation implantable cardioverter defibrillator therapy.Pacing and Clinical Electrophysiology, 1999
- A Comparison of Antiarrhythmic-Drug Therapy with Implantable Defibrillators in Patients Resuscitated from Near-Fatal Ventricular ArrhythmiasNew England Journal of Medicine, 1997